F. Kano et al., 5'-O-ALKYL AND ACYL PRODRUGS OF 1-BETA-D-ARABINOFURANOSYL-E-5-(2-BROMOVINYL)URACIL, Antiviral chemistry & chemotherapy, 5(2), 1994, pp. 74-82
5'-O-Alkyl derivatives of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)
uracil (BV-araU) were synthesized by selective alkylation and deprotec
tion of 2',3'-bis-O-tetrahydropyranyl BV-araU to enhance metabolic sta
bility and evaluated for efficacy as oral prodrugs of BV-araU. For com
parison, their acyl congeners, and 3'-O- and 2'-O-ethyl BV-araU, were
also prepared by direct acylation of BV-araU and by selective protecti
on, alkylation, and deprotection, respectively. The 5'-O-alkyl prodrug
s were stable in acidic solutions, whereas the 5'-O-acyl analogues wer
e unstable under the same conditions. When incubated with enterobacter
ia, the 5'-O-acyl derivatives resulted in the formation of BV-uracil t
hrough non-enzymatic hydrolysis of BV-araU, but the 5'-O-alkyl prodrug
s did not. 5'-O-Short-chain aliphatic alkyl (not longer than butyl) an
d generally acyl prodrugs gave higher blood concentrations of BV-araU
than the aromatic derivatives. Plasma concentrations of BV-araU were e
qual or slightly higher than those after equivalent oral doses of BV-a
raU. 5'-O-Ethyl BV-araU was effective against intracerebral, intraperi
toneal, and cutaneous infections with herpes simplex virus type 1 in m
ice. 5'-O-Short-chain aliphatic alkyl derivatives may prove to be usef
ul oral prodrugs of BV-araU because of increased metabolic stability.